Stocks
BeiGene, Ltd.BGNE
NASDAQHealthcareBiotechnology$184.71+0.49%
A global biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for cancer treatment. Investors track BeiGene for its pipeline of oncology therapies and rapid expansion in international markets, particularly China and the U.S.
Market Cap: $20.2B52W Range: $126.97 – $248.16
Congressional Interest in BeiGene, Ltd. (BGNE)
3 members of Congress have disclosed 4 trades in BeiGene, Ltd. (BGNE), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 3 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
4
Unique Politicians
3
Buys
1
Sells
3
Who in Congress Is Trading BGNE?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-12 | Daniel Goldman | sell | $1K – $15K |
| 2023-07-10 | Daniel Goldman | sell | $1K – $15K |